Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $18.3 million.

  • Tarsus Pharmaceuticals' Cash from Operations rose 31101.48% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.0 million, marking a year-over-year increase of 4613.4%. This contributed to the annual value of -$83.0 million for FY2024, which is 2933.45% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Cash from Operations stood at $18.3 million for Q3 2025, which was up 31101.48% from -$29.4 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Cash from Operations ranged from a high of $20.6 million in Q2 2021 and a low of -$39.3 million during Q4 2023
  • Over the past 5 years, Tarsus Pharmaceuticals' median Cash from Operations value was -$15.3 million (recorded in 2022), while the average stood at -$14.6 million.
  • Data for Tarsus Pharmaceuticals' Cash from Operations shows a peak YoY increase of 90371.53% (in 2021) and a maximum YoY decrease of 49088.18% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Cash from Operations stood at -$12.1 million in 2021, then rose by 10.29% to -$10.9 million in 2022, then crashed by 261.73% to -$39.3 million in 2023, then soared by 43.61% to -$22.2 million in 2024, then surged by 182.31% to $18.3 million in 2025.
  • Its Cash from Operations was $18.3 million in Q3 2025, compared to -$29.4 million in Q2 2025 and -$20.7 million in Q1 2025.